Literature DB >> 12091846

Results of systematic voiding cystourethrography in infants with antenatally diagnosed renal pelvis dilation.

Khalid Ismaili1, Fred E Avni, Michelle Hall.   

Abstract

OBJECTIVES: To assess the yield of neonatal renal ultrasonography as a predictor of abnormalities on voiding cystourethrography (VCUG). STUDY
DESIGN: We prospectively followed 264 infants with antenatal renal pelvis dilation. Two successive neonatal renal ultrasound examinations were performed at day 5 and 1 month after birth. VCUG was performed in all infants.
RESULTS: Neonatal ultrasound findings were abnormal in 190 infants (72% of total). Among them, 63 (33%) had an abnormal VCUG. The most common abnormalities were primary vesico-ureteral reflux (VUR) in 30 infants, VUR into the lower pole of a duplex kidney in 14, refluxing megaureter in 9, posterior urethral valves in 5, and ureterocele in 5. When both neonatal ultrasound findings were normal (74 infants), the VCUG showed abnormalities in only 5 (6.7%) patients (4 low-grade primary VUR and 1 posterior urethral valve). The sensitivity, specificity, positive predictive value, and negative predictive value of 2 successive ultrasound scans in the neonatal period to predict an abnormality on VCUG were 93%, 35%, 33%, and 93%, respectively.
CONCLUSIONS: A normal-appearing urinary tract on 2 successive neonatal ultrasound scans rarely coexists with abnormal findings at VCUG. Therefore, in such patients, VCUG does not seem justified.

Entities:  

Mesh:

Year:  2002        PMID: 12091846     DOI: 10.1067/mpd.2002.125493

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  24 in total

1.  Current management of infants with fetal renal pelvis dilation: a survey by French-speaking pediatric nephrologists and urologists.

Authors:  Khalid Ismaili; Fred E Avni; Amy Piepsz; Karl M Wissing; Pierre Cochat; Didier Aubert; Michelle Hall
Journal:  Pediatr Nephrol       Date:  2004-07-06       Impact factor: 3.714

2.  [Fetal genitourinary anomalies Perinatal and postnatal management with imaging techniques].

Authors:  I Gassner
Journal:  Radiologe       Date:  2005-12       Impact factor: 0.635

Review 3.  Management of fetal hydronephrosis.

Authors:  Jenny Yiee; Duncan Wilcox
Journal:  Pediatr Nephrol       Date:  2007-08-02       Impact factor: 3.714

Review 4.  Evolution of fetal ultrasonography.

Authors:  F E Avni; T Cos; M Cassart; A Massez; C Donner; K Ismaili; M Hall
Journal:  Eur Radiol       Date:  2006-05-30       Impact factor: 5.315

5.  Postnatal imaging of prenatally detected hydronephrosis-when is voiding cystourethrogram necessary?

Authors:  Sofia Visuri; Reetta Kivisaari; Timo Jahnukainen; Seppo Taskinen
Journal:  Pediatr Nephrol       Date:  2018-04-07       Impact factor: 3.714

6.  To V(CUG) or not to V(CUG) in infants with prenatal hydronephrosis?

Authors:  Sisir Botta; Hillary L Copp
Journal:  J Urol       Date:  2014-06-18       Impact factor: 7.450

7.  Clinical spectrum of antenatally detected urinary tract abnormalities with respect to hydronephrosis at postnatal ultrasound scan.

Authors:  Ibrahim Gokce; Nese Biyikli; Halil Tugtepe; Tufan Tarcan; Harika Alpay
Journal:  Pediatr Surg Int       Date:  2012-03-18       Impact factor: 1.827

8.  Antenatal hydronephrosis: infants with minor postnatal dilatation do not need prophylaxis.

Authors:  Karl-Johan Lidefelt; Maria Herthelius
Journal:  Pediatr Nephrol       Date:  2008-06-17       Impact factor: 3.714

Review 9.  Fetal hydronephrosis: is there hope for consensus?

Authors:  Sanna Toiviainen-Salo; Laurent Garel; Andrée Grignon; Josee Dubois; Françoise Rypens; Jacques Boisvert; Gilles Perreault; Jean Claude Decarie; Denis Filiatrault; Chantale Lapierre; Marie-Claude Miron; Nancy Bechard
Journal:  Pediatr Radiol       Date:  2004-04-24

10.  Voiding cystourethrogram in the diagnosis of vesicoureteric reflux in children with antenatally diagnosed hydronephrosis.

Authors:  R B Nerli; S S Amarkhed; I R Ravish
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.